Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) EPS (Basic): 2009-2024

Historic EPS (Basic) for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$5.26.

  • Cytokinetics' EPS (Basic) fell 87.50% to -$2.55 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.29, marking a year-over-year decrease of 16.91%. This contributed to the annual value of -$5.26 for FY2024, which is 3.49% up from last year.
  • Latest data reveals that Cytokinetics reported EPS (Basic) of -$5.26 as of FY2024, which was up 3.49% from -$5.45 recorded in FY2023.
  • Over the past 5 years, Cytokinetics' EPS (Basic) peaked at -$1.97 during FY2020, and registered a low of -$5.45 during FY2023.
  • Over the past 3 years, Cytokinetics' median EPS (Basic) value was -$5.26 (recorded in 2024), while the average stood at -$5.01.
  • Its EPS (Basic) has fluctuated over the past 5 years, first grew by 6.64% in 2020, then tumbled by 54.64% in 2022.
  • Over the past 5 years, Cytokinetics' EPS (Basic) (Yearly) stood at -$1.97 in 2020, then tumbled by 42.13% to -$2.80 in 2021, then slumped by 54.64% to -$4.33 in 2022, then fell by 25.87% to -$5.45 in 2023, then grew by 3.49% to -$5.26 in 2024.